124 studies found for:    "Expanded Access" [STUDY-TYPES] | Open Studies
Show Display Options
Rank Status Study
1 Available EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Sofosbuvir;   Drug: Ribavirin
2 Available Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
Conditions: GBM;   Glioblastoma Multiforme
Intervention: Biological: DCVax-L
3 Available Cartilage Tissue Engineering
Condition: Mesenchymal Stem Cells
Intervention: Other: total knee / hip replacement
4 Available Emergency/Compassionate Use PFO Occluder
Conditions: Patent;   Foramen;   Ovale;   PFO
Intervention: Device: Device closure with the AMPLATZER PFO Occluder
5 Available Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: nintedanib
6 Available Post Study Continuation of C7 for G1D
Conditions: Glut1 Deficiency Syndrome;   Glucose Transporter Type 1 Deficiency Syndrome
Intervention: Drug: Triheptanoin
7 Available Compassionate Use of Stanate (TM) [Stannsoporfin]
Conditions: Neonatal Jaundice;   Hyperbilirubinemia
Intervention: Drug: Stanate (TM) [stannsoporfin, tin-mesoporphyrin]
8 Unknown  Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4 diaminopyridine
9 Available Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG)
10 Available 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
Conditions: Carcinoid Tumors;   Islet Cell (Pancreatic NET);   Other Neuroendocrine Tumors
Intervention: Drug: 68Ga-DOTA TATE
11 Unknown  Weight-bearing Measuring Device to Determine Normative Percentage Body-Weight/Weight-Bearing Values and Weight-bearing Gait Characteristics
Conditions: Percentage Body-Weight;   Weight-Bearing Values;   Weight-bearing Gait Characteristics
Intervention: Device: SmartStep insole
12 Available Prevention of Transmission of Sexually Transmitted Diseases in the Youth Through Effective Intervention,
Condition: HIV
Intervention: Behavioral: Lifestyle Counseling
13 Available A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma
Condition: Liver Cancer
Intervention: Device: Theraspheres
14 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
15 Available Accuracy and Reliability of GSA for Remnant Liver Function
Condition: Both Benign and Malignant Liver Mass
Intervention: Device: 99mTc-GSA
16 Available Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
Condition: Lambert Eaton Myasthenic Syndrome
Intervention: Drug: 3, 4-Diaminopyridine
17 Available Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants
Conditions: Hematologic Malignancies;   Inborn Errors of Metabolism Disorders;   Immune Deficiencies
Intervention: Biological: CliniMACS CD34 Reagent System
18 Available Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage
Condition: Cholestasis of Parenteral Nutrition
Intervention: Drug: Omegaven 10%
19 Available An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
Condition: Acromegaly
Intervention: Drug: Pasireotide long acting release formulation
20 Available Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Condition: Patient 0001-000412 Under Study P05538
Intervention: Drug: ficlatuzumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years